Who Owns Inhibrx Biosciences Stock?
NASDAQ: INBXHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 90.65%
- Institutions (% of float)
- 117.86%
- Held by insiders
- 23.08%
- Institutional holders
- 223
- Institutions 76.9%
- Insiders 23.1%
- Public and other 0.0%
Who owns Inhibrx Biosciences stock?
Institutional investors own about 90.7% of Inhibrx Biosciences's shares, spread across 223 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 23.08% of INBX.
The largest institutional holders are Morgan Stanley (8.89%), Perceptive Advisors Llc (8.82%) and Sanofi (7.87%). Together, the top 10 institutions control 62.9% of shares outstanding. In their latest filings, 7 of the top 10 institutions increased their INBX positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of INBX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Morgan Stanley | 1.31M | 8.89% | +3.6% |
| Perceptive Advisors Llc | 1.30M | 8.82% | -10.1% |
| Sanofi | 1.16M | 7.87% | 0.0% |
| Viking Global Investors, L.P. | 1.12M | 7.64% | -21.8% |
| HighTower Advisors, LLC | 870.55K | 5.92% | +0.0% |
| Bank of America Corporation | 841.14K | 5.72% | +2473.6% |
| Blackrock Inc. | 825.97K | 5.61% | +3.4% |
| Schonfeld Strategic Advisors Llc | 697.59K | 4.74% | +173.8% |
| State Street Corporation | 640.46K | 4.35% | +16.3% |
| Vanguard Capital Management LLC | 492.48K | 3.35% | +1.2% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of INBX
| Fund | Shares | % Held |
|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 423.40K | 2.88% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 369.64K | 2.51% |
| SmallCap World Fund Inc | 353.29K | 2.40% |
| iShares Trust-iShares Russell 2000 ETF | 243.45K | 1.65% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 109.88K | 0.75% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 103.94K | 0.71% |
| iShares Trust-iShares Biotechnology ETF | 81.16K | 0.55% |
| First TRT Exch-Trd AlphaDEX Fd.-First TRT Small Cap Growth AlphaDEX Fd | 80.17K | 0.54% |
| iShares Trust-iShares Russell 2000 Growth ETF | 72.68K | 0.49% |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 61.55K | 0.42% |
Frequently asked questions
Who is the largest shareholder of Inhibrx Biosciences?
Morgan Stanley is the largest institutional shareholder of INBX, owning 8.89% of shares outstanding (1.31M shares) as of its latest 13F filing.
What percentage of Inhibrx Biosciences is owned by institutions?
Institutions own about 90.7% of INBX shares and 117.9% of the public float.
How much of Inhibrx Biosciences do insiders own?
Insiders, such as officers and directors, own about 23.08% of INBX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.